Rahmer Peter 4

What Happened

• Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics (RLAY), reported an ESPP purchase and two open-market sales. He acquired 994 shares on 2025-12-31 under the company ESPP at $2.99/share (cost ~$2,972). He sold 11,684 shares on 2026-01-27 at $7.62 ($89,032) and 1,354 shares on 2026-01-28 at $8.45 ($11,441), for total proceeds of about $100,473. The sales were recorded as open-market disposals.

Key Details

• Transaction types: A (ESPP acquisition) and S (open-market sales). Reporting person voluntarily reported the ESPP purchase.
• Dates & prices:
  • 2025-12-31: ESPP purchase — 994 shares @ $2.99 ( ~$2,972)
  • 2026-01-27: Sale — 11,684 shares @ $7.62 ( ~$89,032)
  • 2026-01-28: Sale — 1,354 shares @ $8.45 ( ~$11,441)
• Sales totaled ~13,038 shares and ~$100,473 in proceeds.
• Footnotes: ESPP shares were purchased at 85% of the closing price on July 1, 2025 (per plan). The reported sales on Jan 27 and Jan 28 were to cover income tax withholding upon RSU vesting (the reporting person had no discretion; transactions were per company RSU withholding policies).
• Holdings note: filing discloses substantial RSU-related holdings (footnotes reference shares underlying RSUs). The Form 4 was filed on 2026-01-29 covering transactions through 2026-01-27/01-28.

Context

• The ESPP purchase is a small, low-cost acquisition (often viewed as routine participation in an employee plan). The two sales were described as mandatory tax-withholding sales tied to RSU vesting, not discretionary market-timed trades. Such withholding sales are common when RSUs vest and do not necessarily indicate insider sentiment about the stock.